Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: Of the 577 patients treated, 424 were evaluable for response. Anagrelide in doses of 0.5 mg to 1.0 mg four times a day reduced the platelet count by 50%, or to less than 600,000/mm3, for at least 28 days in 396 of the 424 (93%) evaluable patients. Acquired resistance to the drug was not observed. Major side effects were neurologic, gastrointestinal, and cardiac. In more than 5 years, 16% of patients discontinued treatment because of side effects. CONCLUSIONS: Our experience suggests that anagrelide should become a useful agent in controlling the thrombocythemia seen in chronic myeloproliferative diseases and can be effective in patients in whom treatment with currently available agents has failed.
|
Authors | |
Journal | The American journal of medicine
(Am J Med)
Vol. 92
Issue 1
Pg. 69-76
(Jan 1992)
ISSN: 0002-9343 [Print] United States |
PMID | 1731512
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Quinazolines
- anagrelide
- Hydroxyurea
|
Topics |
- Aged
- Clinical Protocols
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Humans
- Hydroxyurea
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Platelet Aggregation Inhibitors
(adverse effects, therapeutic use)
- Platelet Count
- Quinazolines
(administration & dosage, adverse effects, therapeutic use)
- Thrombocytosis
(blood, drug therapy, mortality)
- Treatment Outcome
|